NCT04802759 2026-03-16
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Hoffmann-La Roche
Phase 1/2 Recruiting
Clinical Trials
19 trialsNCT05862285 2026-03-13
UmbrellaMAX
Hoffmann-La Roche
Phase 3 Recruiting
NCT05968326 2026-03-12
IMCODE003
Genentech, Inc.
Phase 2 Recruiting
NCT03768063 2026-01-29
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05450562 2026-01-14
Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors
Sanofi
Phase 1/2 Terminated
NCT03148418 2026-01-13
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05112965 2026-01-07
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT00781612 2025-12-24
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Genentech, Inc.
Phase 2 Active not recruiting
NCT03498521 2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2 Completed
NCT04196530 2025-11-12
EIK1001
Eikon Therapeutics
Phase 1 Completed
NCT02794571 2024-12-05
Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors
Genentech, Inc.
Phase 1 Completed
NCT03637764 2023-07-10
Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies
Sanofi
Phase 1/2 Terminated
NCT04869501 2023-04-28
Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer
I-Mab Biopharma US Limited
No longer available
NCT02410512 2022-04-01
A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT03835949 2022-04-01
Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer
Tracon Pharmaceuticals Inc.
Phase 1 Unknown
NCT02367781 2021-08-09
IMpower130
Hoffmann-La Roche
Phase 3 Completed
NCT02458638 2021-06-04
A Study of Atezolizumab in Advanced Solid Tumors
Hoffmann-La Roche
Phase 2 Completed
NCT01633970 2020-10-08
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT01688206 2018-10-05
A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Completed